论文部分内容阅读
目的观察纤溶酶联用马来酸桂哌齐特治疗脑梗死的临床疗效。方法将84例急性脑梗死患者随机分为两组,治疗组42例,纤溶酶100U+0.9%氯化钠注射液100 ml,ivdrip,1次/d×14 d,同时给予马来酸桂哌齐特注射液240 mg+0.9%氯化钠注射液250 ml,ivdrip,1次/d×14,对照组42例,给予丹红注射液20 ml+0.9%氯化钠注射液250 ml,ivdrip,1次/d×14,分别观察两组临床疗效及实验室指标的变化。结果治疗组有效率为90.48%,对照组为59.52%差异有显著意义(P<0.01)。治疗组实验室指标及纤维蛋白原等均降低明显优于对照组(P<0.01)。两组均无明显不良反应。结论应用纤溶酶联合马来酸桂哌齐特治疗急性脑梗死有明显疗效。
Objective To observe the clinical efficacy of plasmin combined with cinepazide maleate in the treatment of cerebral infarction. Methods Eighty-four patients with acute cerebral infarction were randomly divided into two groups: treatment group (n = 42), plasmin 100 U + 0.9% sodium chloride injection 100 ml, iv drip, once daily for 14 days, Pazidet injection 240 mg + 0.9% sodium chloride injection 250 ml, ivdrip, 1 / d × 14, the control group of 42 cases, Danhong injection of 20 ml + 0.9% sodium chloride injection 250 ml, ivdrip, once / d × 14, were observed in two groups of clinical efficacy and laboratory changes in indicators. Results The effective rate was 90.48% in the treatment group and 59.52% in the control group (P <0.01). The indexes of laboratory and fibrinogen in the treatment group were significantly lower than those in the control group (P <0.01). No significant adverse reactions in both groups. Conclusion The application of plasmin combined with cinepazide maleate in the treatment of acute cerebral infarction has a significant effect.